1. Home
  2. ARVN vs RNST Comparison

ARVN vs RNST Comparison

Compare ARVN & RNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$7.43

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

RNST

Renasant Corporation

N/A

Current Price

$39.28

Market Cap

3.6B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ARVN
RNST
Founded
2015
1904
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
3.6B
IPO Year
2018
1997

Fundamental Metrics

Financial Performance
Metric
ARVN
RNST
Price
$7.43
$39.28
Analyst Decision
Buy
Buy
Analyst Count
16
7
Target Price
$13.93
★ $48.14
AVG Volume (30 Days)
★ 703.7K
522.0K
Earning Date
11-04-2026
10-27-2026
Dividend Yield
N/A
★ 2.47%
EPS Growth
★ 58.84
N/A
EPS
1.70
★ 1.88
Revenue
★ $262,600,000.00
N/A
Revenue This Year
$12.76
$12.18
Revenue Next Year
N/A
$3.21
P/E Ratio
★ $4.40
$21.00
Revenue Growth
N/A
★ N/A
52 Week Low
$6.97
$33.04
52 Week High
$14.22
$44.54

Technical Indicators

Market Signals
Indicator
ARVN
RNST
Relative Strength Index (RSI) 38.45 27.31
Support Level N/A $35.04
Resistance Level $8.52 $40.84
Average True Range (ATR) 0.31 0.66
MACD -0.07 -0.13
Stochastic Oscillator 32.09 0.00

Price Performance

Historical Comparison
ARVN
RNST

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About RNST Renasant Corporation

Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has two reportable segments: Community banks and Wealth management. With its Community Banks segment, the company provides a range of financial services to individuals and small businesses. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.

Share on Social Networks: